CD4 and HIV infectious disease: Ex vivo treatment of HIV-infected PBMCs with LtxA led to a significant reduction in viral DNA burden [65], suggesting that while HIV infection may activate CD4+ T cells, doing so makes them more susceptible to LtxA.